Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
58results about How to "Reduces and avoids and and of condition" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
The present invention provides novel 1,3,5-triazinane-2,4,6-trione derivatives, such as compounds of any one of Formulae (I) and (II), and salts thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an siRNA, mRNA, or plasmid DNA). The present invention also provides methods and kits using the compositions for delivering an agent to a subject (e.g., to the liver, spleen, or lung of the subject) or cell and for treating and / or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, and lung diseases.
Owner:MASSACHUSETTS INST OF TECH
Polyamine-fatty acid derived lipidoids and uses thereof
ActiveUS20160002178A1Increase exposureIncrease concentrationOrganic active ingredientsOrganic chemistryRespiratory diseaseFatty acid
The present disclosure provides polyamine-fatty acid derived lipidoids (e.g., compounds of Formula (I) or (II)) and methods of preparing the lipidoids. A described lipidoid includes R—C(═O)—O— moieties (where R is a lipid moiety), which may be hydrolyzed into non-toxic fatty acids. Also provided are compositions including a described lipidoid and an agent (e.g., polynucleotide, small molecule, peptide, or protein). The present disclosure also provides methods, kits, and uses that involve the lipidoids or compositions for delivering an agent to a subject, tissue, or cell and / or for treating and / or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, immunological diseases, gastrointestinal diseases, respiratory diseases, painful conditions, psychiatric disorders, and metabolic disorders.
Owner:MASSACHUSETTS INST OF TECH
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
ActiveUS9315472B2Good curative effectDelay moreOrganic chemistryHeterocyclic compound active ingredientsDiseaseHepatic Diseases
The present invention provides novel 1,3,5-triazinane-2,4,6-trione derivatives, such as compounds of any one of Formulae (I) and (II), and salts thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an siRNA, mRNA, or plasmid DNA). The present invention also provides methods and kits using the compositions for delivering an agent to a subject (e.g., to the liver, spleen, or lung of the subject) or cell and for treating and / or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, and lung diseases.
Owner:MASSACHUSETTS INST OF TECH
Multi-tailed lipids and uses thereof
ActiveUS20160158363A1Good curative effectDelay moreOrganic chemistrySpecial deliveryLipid formationDisease
The present invention provides multi-tailed lipid compounds, and salts and stereoisomers thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an siRNA, mRNA, plasmid DNA, small molecule, protein, peptide). The present invention also provides methods, and kits using the compositions for delivering an agent to a subject (e.g., to the liver, spleen, or lung of the subject) or cell and for treating and / or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, immunological diseases, gastrointestinal diseases (e.g., liver diseases), respiratory diseases (e.g., lung diseases), painful conditions, psychiatric disorders, metabolic disorders, and spleen diseases.
Owner:MASSACHUSETTS INST OF TECH
Therapeutic treatment of select diffuse large b cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes
PendingUS20190292602A1Convenient treatmentReduces and avoids symptomMicrobiological testing/measurementDiffuse large cell lymphomaTherapeutic treatment
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of DLBCL. In particular, the instant disclosure provides a DLBCL classifier that has identified at least five distinct classes of DLBCL cancer, each of which possesses distinct pathogenic mechanisms and outcomes. The instant classifier identifies preferred therapeutic options (including combination therapies) for each such class of DLBCL cancer.
Owner:DANA FARBER CANCER INST INC +1
Polymorphic forms of sodium benzoate and uses thereof
ActiveUS20180111891A1Convenient treatmentReduces and avoids symptomOrganic active ingredientsNervous disorderDiseaseCrystallography
The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 3.7, 5.9, and 26.6 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and / or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).
Owner:SYNEURX INT
Polymorphic forms of sodium benzoate and uses thereof
ActiveUS20180346400A9Good curative effectDelay moreOrganic active ingredientsNervous disorderCrystallographyDisease
The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 3.7, 5.9, and 26.6 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and / or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).
Owner:SYNEURX INT
Polyamine-fatty acid derived lipidoids and uses thereof
ActiveUS9840479B2Good curative effectDelay moreOrganic active ingredientsOrganic chemistryDiseaseRespiratory disease
The present disclosure provides polyamine-fatty acid derived lipidoids (e.g., compounds of Formula (I) or (II)) and methods of preparing the lipidoids. A described lipidoid includes R—C(═O)—O— moieties (where R is a lipid moiety), which may be hydrolyzed into non-toxic fatty acids. Also provided are compositions including a described lipidoid and an agent (e.g., polynucleotide, small molecule, peptide, or protein). The present disclosure also provides methods, kits, and uses that involve the lipidoids or compositions for delivering an agent to a subject, tissue, or cell and / or for treating and / or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, immunological diseases, gastrointestinal diseases, respiratory diseases, painful conditions, psychiatric disorders, and metabolic disorders.
Owner:MASSACHUSETTS INST OF TECH
Max binders as myc modulators and uses thereof
ActiveUS20170233405A1Convenient treatmentReduces and avoids symptomNervous disorderOrganic chemistryDiseaseMedicine
The present disclosure provides compounds of Formula (I′), Formula (I), Formula (II), Formula (II-A), Formula (III), and Formula (IV). The compounds described herein are MAX binders and / or modulators of Myc, Mad, or Mxi1 (e.g., inhibitors of Myc, Mad, or Mxi1), and may be useful in treating a subject with a disease associated with Myc, such as proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions and kits including the compounds described herein, as well as methods of using and uses of the compounds, compositions, and kits.
Owner:MASSACHUSETTS INST OF TECH
Multi-tailed lipids and uses thereof
ActiveUS9895443B2Good curative effectDelay moreOrganic chemistrySpecial deliveryPlasmid dnaRespiratory disease
Owner:MASSACHUSETTS INST OF TECH
Block co-poly(metal organic nanostructures) (bcpmons) and uses thereof
ActiveUS20180258233A9Good curative effectDelay moreGroup 8/9/10/18 element organic compoundsPharmaceutical non-active ingredientsElastomerPolymer science
The present disclosure provides (block co-polymer)-(metal organic framework) conjugates (BCPMOFs), such as (block co-polymer)-(metal organic nanostructure) conjugates (BCPMONs), and thermoplastic elastomers, gels, and compositions thereof. Exemplary BCPMONs include (block co-polymer)-(metal organic cage) conjugates (BCPMOCs), (block co-polymer)-(metal organic paddlewheel) conjugates, and (block co-polymer)-(metal organic square) conjugates, such as BCPMONs of Formula (A), (B), or (C). Also described herein are macromonomers for preparing the BCPMONs; thermoplastic elastomers, gels, and compositions involving the BCPMONs; methods of preparing the BCPMONs, thermoplastic elastomers, gels, and compositions; and methods of using the BCPMONs, thermoplastic elastomers, gels, and compositions.
Owner:MASSACHUSETTS INST OF TECH
Compositions and Methods for Treatment of Ocular Diseases
ActiveUS20200345634A1Enhanced prevention/treatment of bacterial infectionIncreasing antibiotic contact timeSenses disorderAerosol deliveryWound healingDisease
The present disclosure relates to compositions and methods for treating ocular diseases with antibiotics. In particular, the disclosure relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing.
Owner:KIORA PHARM INC
Thiazolyl-containing compounds for treating proliferative diseases
ActiveUS20170233411A1Convenient treatmentReduces and avoids symptomOrganic chemistryAntineoplastic agentsBruton's tyrosine kinaseSrc family kinase
The present disclosure provides thiazolyl-containing compounds of Formula (I), (II), or (III). The compounds described herein may be able to inhibit protein kinases (e.g., Src family kinases (e.g., hemopoietic cell kinase (HCK)), Bruton's tyrosine kinase (BTK)) and may be useful in treating and / or preventing proliferative diseases (e.g., myelodysplasia, leukemia, lymphoma (e.g., Waldenstrom's macroglobulinemia)) and in inducing apoptosis in a cell (e.g., malignant blood cell). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
Owner:DANA FARBER CANCER INST INC
Block co-poly(metal organic nanostructures) (BCPMONs) and uses thereof
ActiveUS10793683B2Good curative effectDelay moreGroup 8/9/10/18 element organic compoundsPharmaceutical non-active ingredientsElastomerPolymer science
Owner:MASSACHUSETTS INST OF TECH
Polymorphic forms of sodium benzoate and uses thereof
ActiveUS10336679B2Good curative effectDelay moreOrganic active ingredientsNervous disorderDiseaseSodium benzoate
The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2θ of approximately 3.7, 5.9, and 26.6 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and / or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).
Owner:SYNEURX INT
D-amino acid oxidase inhibitors and therapeutic uses thereof
ActiveUS20190112289A1Convenient treatmentReduces and avoids symptomOrganic active ingredientsNervous disorderDouble bondSingle bond
The present invention relates to compounds of Formula (I):or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent is a single bond or a double bond; each of X, Y, and Z, independently, is aryl, heteroaryl, aralkyl, H, or absent; each of L1 and L2, independently, is a moiety selected from O, CH2, C═O, C2-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, —((CH2)n—W)—, wherein n=0, 1, 2, 3, 4, or 5, and W is O or S, or absent; and when L2 is absent, Z is aryl or heteroaryl fused with BC. Also provided in the present invention is a method for inhibiting, treating and / or reducing the risk of a neuropsychiatric disorder, comprising administering a subject in need a composition comprising a compound of Formula (I).
Owner:SYNEURX INT
Urea derivatives and uses thereof
The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and / or preventing diseases associated with abnormal or pathological angiogenesis and / or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
Owner:KALA PHARMA
Inhibitors of plasma kallikrein and uses thereof
Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and / or compositions described herein.
Owner:TAKEDA PHARMA CO LTD
O-glcnac transferase (OGT) inhibitors and uses thereof
InactiveUS20170166558A1Convenient treatmentReduces and avoids symptomOrganic chemistryPharmaceutical active ingredientsDiabetes mellitusAGT II
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +1
Fused bicyclic pyrimidine derivatives and uses thereof
ActiveUS20180369243A9Good curative effectDelay moreOrganic chemistryAntineoplastic agentsAutoimmune conditionIsotopic labeling
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase (e.g. a protein kinase (e.g. a cyclin-dependent kinase (CDK) (e.g. CDK7, CDK12, or CDK13) or a lipid kinase such as a phosphatidylinositol-5-phosphate 4-kinase (PIP4K) (e.g., PI5P4Kα, PI5P4Kβ, or PI5P4Kγ)) in the subject.
Owner:DANA FARBER CANCER INST INC
Mutagenic nucleoside analogs and uses thereof
InactiveUS20170313736A1Improve therapeutic efficacyDelay moreOrganic active ingredientsSugar derivativesCancer cellPharmaceutical drug
The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs are expected to show multiple tautomerism and may increase the mutation of an RNA and / or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and / or electron-withdrawing groups to increase or decrease the pKa (e.g., to a pKa between 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits.
Owner:MASSACHUSETTS INST OF TECH
Polymorphic forms of sodium benzoate and uses thereof
ActiveUS11369579B2Reduce riskGood curative effectOrganic active ingredientsNervous disorderSodium benzoateMedicinal chemistry
Owner:SYNEURX INT
Brush prodrugs and uses thereof
PendingUS20210386861A1Low molecular weightImprove narrow therapeutic indexRuthenium organic compoundsPeptide/protein ingredientsPharmaceutical SubstancesPolymer
The present disclosure provides, in some aspects, macromonomers of Formula (I), and salts thereof; methods of preparing the macromonomers, and salts thereof; Brush prodrugs (polymers); methods of preparing the Brush prodrugs; compounds of Formula (II); conjugates of Formula (III), and salts thereof; pharmaceutical compositions comprising a Brush prodrug, or a conjugate or a salt thereof; kits comprising: a macromonomer or a salt thereof, a Brush prodrug, a compound, a conjugate or a salt thereof, or a pharmaceutical composition; methods of using the Brush prodrugs, or conjugates or salts thereof; and uses of the Brush prodrugs, and conjugates or salts thereof. These chemical entities may be useful in delivering pharmaceutical agents to a subject or cell.
Owner:MASSACHUSETTS INST OF TECH
Max binders as MYC modulators and uses thereof
The present disclosure provides compounds of Formula (I′), Formula (I), Formula (II), Formula (II-A), Formula (III), and Formula (IV). The compounds described herein are MAX binders and / or modulators of Myc, Mad, or Mxi1 (e.g., inhibitors of Myc, Mad, or Mxi1), and may be useful in treating a subject with a disease associated with Myc, such as proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions and kits including the compounds described herein, as well as methods of using and uses of the compounds, compositions, and kits.
Owner:MASSACHUSETTS INST OF TECH
Lithium salts of N-substituted glycine compounds and uses thereof
ActiveUS10226442B2Good curative effectDelay moreNervous disorderInorganic active ingredientsArylLithium
Owner:SYNEURX INT
Lithium salts of n-substituted glycine compounds and uses thereof
ActiveUS20190008813A1Great effectGood curative effectNervous disorderInorganic active ingredientsN-substituted GlycinesLithium
The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I):in which R1, R2, and R3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R1, R2, and R3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).
Owner:SYNEURX INT
4,6-pyrimidinylene derivatives and uses thereof
ActiveUS20180110778A1Reduce and slow and and prevent activityHigh binding affinityOrganic active ingredientsOrganic chemistryNeoplasmLung cancer
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase (e.g. a protein kinase (e.g. a cyclin-dependent kinase (CDK) (e.g. CDK7, CDKl2, or CDKl3) or a lipid kinase such as a phosphatidylinositol-5-phosphate 4-kinase (PIP4K) (e.g., PI5P4Kα, PI5P4Kβ, or PI5P4Kγ)) in the subject.
Owner:DANA FARBER CANCER INST INC
Targeting egln1 in cancer
PendingUS20220090083A1Convenient treatmentReduces and avoids symptomScreening processOxidoreductasesOncologyCancer research
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of EGLN1-dependent cancers. In particular, the instant disclosure provides for identification of a cancer as EGLN1-dependent, and selection and / or administration of an inhibitor of EGLN1 or VHL (Von Hippel-Lindau Tumor Suppressor) as a therapeutic agent for such a cancer and / or subject having or at risk of developing such a cancer.
Owner:INST CARLOS SLIM DE LA SALUD A C +2
Salts of cycloserine compounds and applications thereof
ActiveUS10485790B1Convenient treatmentReduces and avoids symptomAntibacterial agentsNervous disorderBACTERIAL INFECTIOUS DISEASESMedicinal chemistry
The present invention relates to salts of formula [A][B], wherein [A] is a cation form of a cycloserine compound and [B] is an anion form of a compound of Formula (I):wherein the ratio between the cycloserine compound and the compound of formula (I) ranges from 10:1 to 1:10. The salts described herein have improved properties, including greatly increased stability and decreased hygroscopicity. Also provided in the present invention are methods for treating and / or reducing the risk of a neuropsychiatric disorder and / or a bacterial infectious disease (e.g., tuberculosis), comprising administering a subject in need a composition comprising salts of formula [A][B] described herein.
Owner:SYNEURX INT
Small molecules that block proteasome-associated ubiquitin receptor rpn13 function and uses thereof
PendingUS20210130324A1Convenient treatmentReduces and avoids and and of conditionOrganic chemistryPharmaceutical non-active ingredientsNeoplasmMolecular biology
Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety (e.g., RA190) that is a binder of the ubiquitin receptor RPN13 to induce degradation of RPN13 and thereby inhibit proteasome function. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and / or preventing diseases (e.g., proliferative diseases, cancers, benign neoplasms, pathological angiogenesis, inflammatory diseases, and autoimmune diseases). Provided also are methods of inducing the degradation of ubiquitin receptor RPN13 by administering a bifunctional compound or composition described herein, wherein one component of the bifunctional compound is a binder of an E3 ubiquitin ligase (e.g., lenalidomide, thalidomide) and another component of the compound is a binder of ubiquitin receptor RPN13 (e.g., RA190) in a subject.
Owner:DANA FARBER CANCER INST INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com